A process for the production of a formulation of HIV attachment inhibitor piperazine tris salt prodrug compound involves dissolving the prodrug compound in a solvent to form a solution； adding a first quantity of a first anti-solvent to the solution； then dispersing a first quantity of HPMC in the solution； adding a second quantity of the first anti-solvent to the solution； dispersing a second quantity of HPMC in the solution； then adding a second anti-solvent to the solution so as to crystallize the compound with the HPMC and thereby form the formulation, wherein the second anti-solvent is a combination of acetone and isopropyl acetate (IPAC). The formulation is then washed, and dried.
